From WikiProjectMed
Jump to navigation Jump to search
Monoclonal antibody
TypeWhole antibody
TargetComplement C5
Trade namesVeopoz
Other namesREGN-3918, pozelimab-bbfg
Clinical data
Routes of
Intravenous, subcutaneous
External links
License data
Legal status
Chemical and physical data
Molar mass144496.11 g·mol−1

Pozelimab, sold under the brand name Veopoz, is a medication used to treat CD55-deficient protein-losing enteropathy (CHAPLE disease).[1][2]

Common side effects include upper respiratory tract infections, fractures, hives, and alopecia.[2] It is a complement inhibitor.[1][2]

Pozelimab was approved for medical use in the United States in 2023.[2][3] It is produced using recombinant DNA technology in Chinese hamster ovary cells.[1]

Medical uses

Pozelimab is indicated for the treatment of people with CD55-deficient protein-losing enteropathy, also known as CHAPLE disease.[1][2]

CHAPLE—which stands for complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy—is an inherited immune disease that causes the complement system (the part of your immune system that defends the body against injury and foreign invaders like bacteria and viruses) to become overactive.[2] It is caused by mutations of the complement regulator CD55 gene, which can lead to the complement system attacking the body's own cells.[2] CHAPLE disease is a rare disease, with fewer than 100 participants diagnosed worldwide.[2] Symptoms can include abdominal pain, nausea, vomiting, diarrhea, loss of appetite, weight loss, impaired growth, and edema (swelling).[2] Severe thrombotic vascular occlusions (blockage of blood vessels) can also occur among participants with CHAPLE disease, which can be life-threatening.[2]

Side effects

The US prescribing label for pozelimab has a boxed warning for serious meningococcal infections.[1][2]

The most common adverse reactions (in 2 or more patients) are upper respiratory tract infection, fracture, urticaria, and alopecia.[4]


The efficacy and safety of pozelimab was evaluated in a single-arm study (NCT04209634), in which participants' outcomes were compared to pre-treatment data in participants with active CD55-deficient protein-losing enteropathy who had hypoalbuminemia.[2] Participants' diagnoses were based on a clinical history of protein-losing enteropathy symptoms and with a confirmed genotype of biallelic CD55 loss-of-function mutation.[2] Active CD55-deficient protein-losing enteropathy was defined as hypoalbuminemia (serum albumin concentration of ≤3.2 g/dL) with one or more of the following signs or symptoms within the last six months: diarrhea, abdominal pain, peripheral edema, or facial edema.[2]

The U.S. Food and Drug Administration (FDA) granted the application for pozelimab fast track, orphan drug, and rare pediatric disease designations.[2] It is the first FDA-approved treatment for CHAPLE disease.[2][5] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[6]

Society and culture

Legal status

Pozelimab was approved for medical use in the United States in August 2023.[2][3] The FDA granted the application for pozelimab fast track, priority review, and orphan drug designations.[6]


Pozelimab is the international nonproprietary name.[7]


  1. 1.0 1.1 1.2 1.3 1.4 1.5 "Veopoz- pozelimab injection, solution". DailyMed. 18 August 2023. Archived from the original on 9 July 2024. Retrieved 6 October 2023.
  2. 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 "FDA approves first treatment for CD55-deficient protein-losing enteropathy (CHAPLE disease)". U.S. Food and Drug Administration (FDA). 18 August 2023. Archived from the original on 19 August 2023. Retrieved 18 August 2023. Public Domain This article incorporates text from this source, which is in the public domain.
  3. 3.0 3.1 "Veopoz (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease" (Press release). Regeneron Pharmaceuticals. 18 August 2023. Archived from the original on 9 July 2024. Retrieved 18 August 2023 – via GlobeNewswire.
  4. Monograph
  5. Hoy SM (November 2023). "Pozelimab: First Approval". Drugs. 83 (16): 1551–1557. doi:10.1007/s40265-023-01955-9. PMID 37856038. S2CID 264303931. Archived from the original on 2024-07-09. Retrieved 2024-01-17.
  6. 6.0 6.1 New Drug Therapy Approvals 2023 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 10 January 2024. Retrieved 9 January 2024.
  7. World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). hdl:10665/330879.

External links

  • Clinical trial number NCT04209634 for "Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)" at ClinicalTrials.gov